Erasca Inc. has obtained IND clearance by the FDA for ERAS-4001, an oral selective pan-KRAS inhibitor, for the treatment of patients with KRAS-mutant solid tumors.
Radiopharm Theranostics Ltd. has reported preclinical data from studies with the Lu177-B7H3-monoclonal antibody (mAb) RV-01 demonstrating favorable biodistribution and showing that RV-01 maintained high tumor uptake.
LIN28 is a family of RNA-binding proteins that regulate stem cell biology and pluripotency and are involved in oncogenesis through the interaction with tumor suppressor microRNA let-7. The expression of LIN28 leads to the loss of function of let-7, leading to tumorigenesis, and has been tied to tumor aggressiveness and poor survival in children with brain tumors.
The systemic virotherapy strategy involves not only the direct delivery of therapeutic payloads encoded by viruses to tumors, but also the modification of the tumor microenvironment, aiming to target both primary and metastatic lesions. At the ongoing American Society of Clinical Oncology (ASCO) meeting, researchers from Calidi Biotherapeutics Inc. reported the development of a novel approach using a selected and engineered tumor-selective strain of vaccinia virus.
An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22 cancer types, which has identified more than 9,000 proteins from 1,000 tumors. The results reveal which proteins allow for the classification of different cancer types, biomarkers and potential therapeutic targets, which are now available to the entire scientific community.
Gan & Lee Pharmaceuticals Co. Ltd. has described protein cereblon (CRBN) inhibitors and proteolysis targeting chimera (PROTAC) compounds reported to be useful for the treatment of cancer.
Treeline Biosciences Inc. has divulged proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1) targeting moiety via a linker acting as Bcl-xl degradation inducers reported to be useful for the treatment of cancer.
Among gynecological cancers, ovarian cancer is the deadliest one and with the worst prognosis primarily due to resistance to platinum-based therapies. Esculetin has been shown to exert antitumoral effects in some cancer types, but its effect on ovarian cancer is not well known.
Multiple myeloma (MM) is a complex and heterogeneous blood cancer, and current risk assessment tools like the Revised International Staging System (R-ISS) have limitations in accurately predicting prognosis, especially for the intermediate-risk R-ISS II group.
The polarization of macrophages is crucial in modulating the tumor microenvironment and impacting cancer development. Long noncoding RNAs (lncRNAs) have been identified as key regulators in this process.
RSS
